Skip to main content

Advertisement

SpringerLink
Log in

Estrogen receptor promoter methylation predicts survival in low-grade ovarian carcinoma patients

  • Original Article – Cancer Research
  • Published:
Journal of Cancer Research and Clinical Oncology Aims and scope Submit manuscript

Abstract

Purpose

Ovarian carcinoma is the third most common gynecological cancer and only short recurrence-free survival and overall survival times are archived. The role of the estrogen receptor expression is well studied in breast cancer and breast cancer cell lines. Patients with positive estrogen receptor expression have a lower risk for recurrence and a better overall survival. Previous studies have shown that ESR1 methylation influences ovarian cancer development and might thus play a role regarding prognosis of ovarian carcinoma.

Methods

A total of 75 patients were identified that were treated for ovarian carcinoma by debulking surgery and adjuvant standard chemotherapy. Isolation and bisulfite treatment of genomic DNA from serial sections of surgically resected ovarian carcinoma tissue was performed using commercially available kits. For the detection of methylated ESR1 promoter sequences, real-time methylation-specific PCR was used.

Results

Promoter methylation did not show a correlation between clinical–pathological data for all patients. However, within the subgroup of low-grade ovarian carcinoma patients and patients with an ovarian tumor of low malignant potential methylation of the ESR1 promoter inversely correlated with survival (p = 0.031).

Conclusions

Although small numbers of ovarian carcinoma patients were analyzed, methylation status might be useful as a prognostic marker within the subgroup of low-grade ovarian carcinoma patients. Further studies should investigate a larger cohort and also address the use of demethylation agents with respect to improve patient’s prognosis in this subgroup of ovarian carcinoma patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  • Barton CA, Hacker NF, Clark SJ, O’ Brien PM (2008) DNA methylation changes in ovarian cancer: implications for early diagnosis, prognosis and treatment. Gynecol Oncol 109(1):129–139. doi:10.1016/j.ygyno.2007.12.017

    Article  PubMed  CAS  Google Scholar 

  • Eads CA, Lord RV, Kurumboor SK, Wickramasinghe K, Skinner ML, Long TI, Peters JH, DeMeester TR, Danenberg KD, Danenberg PV, Laird PW, Skinner KA (2000) Fields of aberrant CpG island hypermethylation in Barrett’s esophagus and associated adenocarcinoma. Cancer Res 60:5021–5026

    PubMed  CAS  Google Scholar 

  • Esteller M, Corn PG, Baylin SB, Herman JG (2001) A gene hypermethylation profile of human cancer. Cancer Res 61:3225–3229

    PubMed  CAS  Google Scholar 

  • Feng Q, Deftereos G, Hawes SE, Stern JE, Willner JB, Swisher EM, Xi L, Drescher C, Urban N, Kiviat N (2008) DNA hypermethylation, Her/2-neu overexpression and p53 mutations in ovarian carcinoma. Gynecol Oncol 111(2):320–329. doi:10.1016/j.ygyno.2008.07.036

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  • Gross AL, Kurman RJ, Vang R, Shih IM, Visvanathan K (2010) Precursor lesions of high-grade serous ovarian carcinoma: morphological and molecular characteristics. J Oncol 2010:126295. doi:10.1155/2010/126295

    Article  PubMed  PubMed Central  Google Scholar 

  • Harder J, Engelstaedter V, Usadel H, Lassmann S, Werner M, Baier P, Otto F, Varbanova M, Schaeffner E, Olschewski M, Blum HE, Opitz OG (2009) CpG-island methylation of the ER promoter in colorectal cancer: analysis of micrometastases in lymph nodes from UICC stage I and II patients. Br J Cancer 100(2):360–365. doi:10.1038/sj.bjc.6604859

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  • Houshdaran S, Hawley S, Palmer C, Campan M, Olsen MN, Ventura AP, Knudsen BS, Drescher CW, Urban ND, Brown PO, Laird PW (2012) DNA Methylation profiles of ovarian epithelial carcinoma tumors and cell lines. PLoS ONE 5(2):e9359. doi:10.1371/journal.pone.0009359

    Article  Google Scholar 

  • Huang YW, Jansen RA, Fabbri E, Potter D, Liyanarachchi S, Chan MW, Liu JC, Crijns AP, Brown R, Nephew KP, van der Zee AG, Cohn DE, Yan PS, Huang TH, Lin HJ (2009) Identification of candidate epigenetic biomarkers for ovarian cancer detection. Oncol Rep 22(4):853–861

    PubMed  CAS  PubMed Central  Google Scholar 

  • Issa JP, Ottaviano YL, Celano P, Hamilton SR, Davidson NE, Baylin SB (1994) Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon. Nat Genet 7(4):536–540

    Article  PubMed  CAS  Google Scholar 

  • Issa JP, Zehnbauer BA, Civin CI, Collector MI, Sharkis SJ, Davidson NE, Kaufmann SH, Baylin SB (1996) The estrogen receptor CpG island is methylated in most hematopoietic neoplasms. Cancer Res 56(5):973–977

    PubMed  CAS  Google Scholar 

  • Kurman RJ, Shih IM (2010) The origin and pathogenesis of epithelial ovarian cancer—a proposed unifying theory. Am J Surg Pathol 34(3):433–443. doi:10.1097/PAS.0b013e3181cf3d79

    Article  PubMed  PubMed Central  Google Scholar 

  • Lapidus RG, Ferguson AT, Ottaviano YL, Parl FE, Smith HS, Weitzman SA, Baylin SB, Issa JP, Davidson NE (1996) Methylation of estrogen and progesterone receptor gene 5′ CpG islands correlates with lack of estrogen and progesterone receptor gene expression in breast tumors. Clin Cancer Res 2(5):805–810

    PubMed  CAS  Google Scholar 

  • Lapidus RG, Nass SJ, Davidson NE (1998a) The loss of estrogen and progesterone receptor gene expression in human breast cancer. J Mammary Gland Biol Neoplasia 3(1):85–94

    Article  PubMed  CAS  Google Scholar 

  • Lapidus RG, Nass SJ, Butash KA, Parl FF, Weitzman SA, Graff JG, Herman JG, Davidson NE (1998b) Mapping of ER gene CpG island methylation-specific polymerase chain reaction. Cancer Res 58(12):2515–2519

    PubMed  CAS  Google Scholar 

  • Lenhard M, Lennerova T, Heublein S, Ditsch N, Himsl I, Mayr D, Friese K, Jeschke U (2012) Steroid hormone receptor expression in ovarian cancer: progesterone receptor B as prognostic marker for patient survival. BMC Cancer 12:553

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  • McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL, Davidson M (1996) Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and IV ovarian cancer. New Eng J Med 334:1–6

    Article  PubMed  CAS  Google Scholar 

  • Montavon C, Glos BS, Warton K, Barton CA, Statham AL, Scurry JP, Tabor B, Nguyen TV, Qu W, Samimi G, Hacker NF, Sutherland RL, Clark SJ, O‘Brien PM (2012) Prognostic and diagnostic significance of DNA methylation patterns in high grade serous ovarian cancer. Gynecol Oncol 124:582–588. doi:10.1016/j.ygyno.2011.11.026

    Article  PubMed  CAS  Google Scholar 

  • Newcomb PA, Longnecker MP, Storer BE, Mittendorf R, Baron J, Clapp RW, Bogdan G, Willett WC (1995) Long-term hormone replacement therapy and risk of breast cancer in postmenopausal women. Am J Epidemiol 142(8):788–795

    PubMed  CAS  Google Scholar 

  • O’Doherty AM, Church SW, Russel SE, Nelson J, Hickey I (2002) Methylation status of oestrogen receptor alpha gene promoter sequence in human ovarian epithelial cell lines. Br J Cancer 86(2):282–284

    Article  PubMed  PubMed Central  Google Scholar 

  • Shaw D, Clamp A, Jayson GC (2013) Angiogenesis as a target for the treatment of ovarian cancer. Curr Opin Oncol 25(5):558–565

    Article  PubMed  CAS  Google Scholar 

  • Shi IM, Chen L, Wang C, Gu J, Davidson B, Cope L, Kurman RJ, Xuan J, Wang TL (2010) Distinct DNA methylation profiles in ovarian serous neoplasms and their implications in ovarian carcinogenesis. Am J Obstet Gynecol 203(6):584.e1–584.e22. doi:10.1016/j.ajog.2010.08.003

    Google Scholar 

  • Su HY, Lai HC, Lin YW, Chou YC, Liu CY, Yu MH (2009) An epigenetic marker panel for screening and prognostic prediction of ovarian cancer. Int J Cancer 124(2):387–393. doi:10.1002/ijc.23957

    Article  PubMed  CAS  Google Scholar 

  • Teodoridis JM, Hall J, Marsh S, Kannall HD, Smyth C, Curto J, Siddiqui N, Gabra H, McLeod HL, Strathdee G, Brown R (2005) CpG Island methylation of DNA damage response genes in advanced ovarian cancer. Cancer Res 65(19):8961–8967

    Article  PubMed  CAS  Google Scholar 

  • Teschendorff AE, Menon U, Gentry-Maharaj A, Ramus SJ, Gayther SA, Apostolidou S, Jones A, Lechner M, Beck S, Jacobs IJ, Widschwendter M (2009) An epigenetic signature in peripheral blood predicts active ovarian cancer. PLoS ONE 4(12):e8274. doi:10.1371/journal.pone.0008274

    Article  PubMed  PubMed Central  Google Scholar 

  • Vang R, Shih IM, Kurman RJ (2009) Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems. Adv Anat Pathol 16(5):267–282. doi:10.1097/PAP.0b013e3181b4fffa

    Article  PubMed  PubMed Central  Google Scholar 

  • Watts GS, Futscher BW, Holtan N, Degeest K, Domann FE, Rose SL (2008) DNA methylation changes in ovarian cancer are cumulative with disease progression and identify tumor stage. BMC Med Genomics 1:47. doi:10.1186/1755-8794-1-47

    Article  PubMed  PubMed Central  Google Scholar 

  • Wei SH, Balch C, Paik HH, Kim YS, Baldwin RL, Liyanarchchi S, Li L, Wang Z, Wan JC, Davuluri RV, Karlan BY, Gifford G, Brown R, Kim S, Huang TH, Nephew KP (2006) Prognostik DNA methylation biomarkers in ovarian cancer. Clin Cancer Res 12(9):2788–2794

    Article  PubMed  CAS  Google Scholar 

  • Wiley A, Katsaros D, Chen H, Rigault de la Longrais IA, Beeghly A, Puopolo M, Singal R, Zhang Y, Amoako A, Zelterman D, Yu H (2006) Aberrant promoter methylation of multiple genes in malignant ovarian tumors and in ovarian tumors with low malignant potential. Cancer 107(2):299–308

    Article  PubMed  CAS  Google Scholar 

  • Wrzeszczynski KO, Varadan V, Byrnes J, Lum E, Kamalakaran S, Levine DA, Dimitrova N, Zhang MQ, Lucito R (2011) Identification of tumor suppressors and oncogenes from genomic and epigenetic features in ovarian cancer. PLoS ONE 6(12):e28503. doi:10.1371/journal.pone.0028503

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  • Yang HJ, Liu VWS, Wang Y, Tsang PC, Ngan HY (2006) Differential DNA methylation profiles in gynecological cancers and correlation with clinic-pathological data. BMC Cancer 6:212

    Article  PubMed  PubMed Central  Google Scholar 

  • Yap OWS, Bhat G, Liu L, Tollefsbol TO (2009) Epigenetic modifications of the estrogen receptor β gene in epithelial ovarian cancer cells. Anticancer Res 29(1):139–144

    PubMed  CAS  PubMed Central  Google Scholar 

Download references

Acknowledgments

We thank Simone Hoffmann and Christine Kuhn for their excellent technical support.

Conflict of interest

None of the authors have a conflict of interest to declare.

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynecology, University of Cologne, Kerpener Str. 34, 50931, Cologne, Germany

    Verena Kirn, Claudius Fridrich & Wolfram Malter

  2. Department of Obstetrics and Gynecology, Ludwig-Maximilians University, Campus Innenstadt, Maistrasse 11, 80337, Munich, Germany

    Rong Shi, Sabine Heublein, Julia Knabl, Margit Guenthner-Biller, Ulrich Andergassen, Klaus Friese & Udo Jeschke

  3. Cnopf’sche Kinderklinik/Klinik Hallerwiese, St.-Johannis-Mühlgasse 19, 90419, Nuremberg, Germany

    Julia Knabl

  4. HB-Klinikum Singen, II. Medizinische Klinik, Virchowstrasse 10, 78224, Singen, Germany

    Jan Harder

  5. Institute of Pathology, Ludwig-Maximilians University, Thalkirchner Strasse 36, 80337, Munich, Germany

    Doris Mayr

Authors
  1. Verena Kirn
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rong Shi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sabine Heublein
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Julia Knabl
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Margit Guenthner-Biller
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ulrich Andergassen
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Claudius Fridrich
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Wolfram Malter
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Jan Harder
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Klaus Friese
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Doris Mayr
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Udo Jeschke
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Verena Kirn.

Additional information

Doris Mayr and Udo Jeschke have contributed equally to this work.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kirn, V., Shi, R., Heublein, S. et al. Estrogen receptor promoter methylation predicts survival in low-grade ovarian carcinoma patients. J Cancer Res Clin Oncol 140, 1681–1687 (2014). https://doi.org/10.1007/s00432-014-1729-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00432-014-1729-9

Keywords

Search

Navigation